Ilem-Ozdemir D.Atlihan-Gundogdu E.Ekinci M.Halay E.Ay K.Karayildirim T.Asikoglu M.2024-07-222024-07-22201903624803http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14366The clinical impact and accessibility of 99mTc tracers for cancer diagnosis would be greatly enhanced by the availability of a new, simple, and easy labeling process and radiopharmaceuticals. 5-Fluorouracil is an antitumor drug, which has played an important role for the treatment of breast carcinoma. In the present study, a new derivative of 5-Fluorouracil was synthesized as (1-[{1′-(1′′-deoxy-2′′,3′′:4′′,5′′-di-O-isopropylidene-β-D-fructopyranose-1′′-yl)-1′H-1′,2′, 3′-triazol-4′-yl}methyl]-5-fluorouracil) (E) and radiolabeled with 99mTc. It was analyzed by radio thin layer chromatography for quality control and stability. The radiolabeled complex was subjected to in vitro cell-binding studies to determine healthy and cancer cell affinity using HaCaT and MCF-7 cells, respectively. In addition, in vitro cytotoxicity studies of compound E were performed with HaCaT and MCF-5 cells. The radiochemical purity of the [99mTc]TcE was found to be higher than 90% at room temperature up to 6 hours. The radiolabeled complex showed higher specific binding to MCF-7 cells than HaCaT cells. IC50 values of E were found 31.5 ± 3.4 μM and 20.7 ± 2.77 μM for MCF-7 and HaCaT cells, respectively. The results demonstrated the potential of a new radiolabeled E with 99mTc has selective for breast cancer cells. © 2019 John Wiley & Sons, Ltd.English1 [[1' (1'' deoxy 2'',3'':4'',5'' di o isopropylidene beta dextro fructopyranose 1'' yl) 1'h 1',2', 3' triazol 4' yl]methyl] 5 fluorouracil tc 99mcytotoxic agentfluorouracil derivativeradiopharmaceutical agentreducing agentunclassified drugArticlecell culturecell viabilitydrug cytotoxicitydrug synthesisHaCat cell linehumanhuman cellIC50in vitro studyisotope labelingMCF-7 cell linepHradioactive thin layer chromatographyradioactivityradiochemistrythin layer chromatographytransepithelial electrical resistancetransepithelial resistanceArticle10.1002/jlcr.3804